Halls for sale?
This article was originally published in The Tan Sheet
Executive Summary
Pfizer considering divesting Adams confectionery business, which includes Halls cough drops, and Schick-Wilkinson Sword shaving products, firm says June 27. Businesses "are not aligned with Pfizer's strategic focus on pharmaceuticals and health care," company says. Pfizer notes it is "highly unlikely" individual brands under Adams will be sold piecemeal. However, one possibility includes spinning divisions off into separate businesses; deal could be completed within nine to 12 months. Pfizer maintains its consumer healthcare division enjoys synergies with the Rx business and is an unlikely candidate for divestment. Separately, Pfizer's board of directors announces authorization for repurchase of up to $10 bil. worth of common stock over next 24 months...
You may also be interested in...
Halls Acquisition Brings Cadbury Into “Functional Confectionery” Market
Cadbury Schweppes' purchase of the Halls cough drop brand from Pfizer provides the firm with a foothold in the "functional confectionery" category
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.